In Vitro Study of the Role of Factor IX in Treatment of Breakthrough Bleeds in Patients with Hemophilia A and Inhibitors Receiving Emicizumab
TH Open · 09.04.2026 · 10 (CP)
DOI: 10.1055/a-2834-3178 ↗Kurz gefasst
Fachartikel in der Zeitschrift TH Open, erschienen am 09.04.2026. Verfasst von Maissaa Janbain und 7 weiteren Autor:innen. Beteiligte Einrichtung: Section of Hematology and Medical Oncology, Deming Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana, United State…. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Hemophilia A (HA) is an X-linked disorder characterized by a deficiency of factor VIII (FVIII). Approximately 30% of patients with severe HA (baseline FVIII levels < 1 IU/dL) develop antibodies that neutralize the activity of FVIIIs. Emicizumab, a bispecific monoclonal antibody that has FVIII mimetic activity, is effective at preventing bleeding in patients with HA and has become a standard prophylactic therapy for hemophilia patients with inhibitors. However, breakthrough bleeding and perioperative management still require additional bypassing agents, which increases the risk of thrombosis in these patients.
Methods
This in vitro study compares the hemostatic effect of adding factor IX (FIX) to the plasma of HA patients on emicizumab prophylaxis with the addition of bypassing agents. Blood from 24 HA patients on emicizumab was collected, and plasma samples were spiked with increasing concentrations of recombinant factor VIIa (rFVIIa), activated prothrombin complex concentrate (aPCC), recombinant FIX (rFIX), and plasma-derived FIX (pdFIX). Thrombin generation (TG) was assessed using calibrated automated thrombography. Plasma emicizumab and FIX activity were measured.
Results
TG capacity improved significantly with increasing concentrations of rFVIIa (p < 0.0001), aPCC, rFIX, and pdFIX (p < 0.005). In contrast to high doses of aPCC and rFVIIa, TG parameters obtained with the addition of FIX did not cross the upper limit of normal physiologic ranges.
Conclusion
Our data suggest a possible increased risk of thrombosis with higher concentrations of rFVIIa and aPCC, while adjunctive FIX therapy appears to be safe and effective in improving coagulation in HA patients with inhibitors on emicizumab prophylaxis. Future clinical trials are needed to confirm these results.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Section of Hematology and Medical Oncology, Deming Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana, United States.
- Faculte de Medecine Lyon-Est, Universite Lyon I, UR4609, Hemostase and Thrombose, Lyon, France.
- Unite d'Hemostase Clinique, Hospital Cardiologique Louis Pradel, Hospices Civils de Lyon, Lyon, France.
Zitieren
APA
Janbain, M., Josset, L., Leuci, A., Zakharia, K., Ksayer, R., Nougier, C., Leissinger, C., & Dargaud, Y. (2026). In Vitro Study of the Role of Factor IX in Treatment of Breakthrough Bleeds in Patients with Hemophilia A and Inhibitors Receiving Emicizumab. TH Open, 10(CP). https://doi.org/10.1055/a-2834-3178
Vancouver
Janbain M, Josset L, Leuci A, Zakharia K, Ksayer R, Nougier C, et al. In Vitro Study of the Role of Factor IX in Treatment of Breakthrough Bleeds in Patients with Hemophilia A and Inhibitors Receiving Emicizumab. TH Open. 2026;10(CP). doi:10.1055/a-2834-3178
BibTeX
@article{Janbain2026,
author = {Janbain, Maissaa and Josset, Laurie and Leuci, Alexandre and Zakharia, Karam and Ksayer, Radia and Nougier, Christophe and Leissinger, Cindy and Dargaud, Yesim},
title = {In Vitro Study of the Role of Factor IX in Treatment of Breakthrough Bleeds in Patients with Hemophilia A and Inhibitors Receiving Emicizumab},
journal = {TH Open},
year = {2026},
volume = {10},
number = {CP},
doi = {10.1055/a-2834-3178}
}
EUVIMED